AstraZeneca CEO believes Trump tariffs won't have a significant long-term impact

From Yahoo Finance: 2025-04-29 12:05:00

AstraZeneca CEO Pascal Soriot is not worried about potential pharmaceutical tariffs by the Trump administration. He believes a favorable corporate tax credit could encourage reshoring. The company reported mixed Q1 earnings, with core EPS at $2.49 and revenues at $13.59 billion, missing estimates. AstraZeneca plans to invest $3.5 billion in US manufacturing and R&D. Soriot is advocating for more R&D investment in Europe.



Read more at Yahoo Finance: Trump tariffs ‘not material long term’